Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 238

Similar articles for PubMed (Select 14709740)

1.

Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.

Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K.

J Natl Cancer Inst. 2004 Jan 7;96(1):68-70.

2.

GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancer.

Laitman Y, Jaeger E, Katz L, Tomlinson I, Friedman E.

Genet Res (Camb). 2015 May 20;97:e11. doi: 10.1017/S0016672315000105.

PMID:
25992589
3.

Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage.

Palomaki GE.

J Med Screen. 2015 May 5. pii: 0969141315579701. [Epub ahead of print] No abstract available.

PMID:
25943835
4.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.

J Clin Oncol. 2015 May 4. pii: JCO.2014.59.7401. [Epub ahead of print]

PMID:
25940717
5.

Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.

Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.

Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z.

PMID:
25850536
6.

FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns.

Laitman Y, Ries-Levavi L, Berkensdadt M, Korach J, Perri T, Pras E, Friedman E.

Genet Res (Camb). 2014 Oct 8;96:e11. doi: 10.1017/S0016672314000147.

PMID:
25579682
7.

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.

Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.

Breast Cancer Res Treat. 2015 Jan;149(1):223-7. doi: 10.1007/s10549-014-3218-x. Epub 2014 Dec 6. Erratum in: Breast Cancer Res Treat. 2015 May;151(1):233.

PMID:
25476495
8.

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.

Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan.

9.

To reflex or not: additional BRCA1/2 testing in Ashkenazi Jewish individuals without founder mutations.

Petrucelli N, Mange S, Fulbright JL, Dohany L, Zakalik D, Duquette D.

J Genet Couns. 2015 Apr;24(2):285-93. doi: 10.1007/s10897-014-9762-z. Epub 2014 Sep 9.

PMID:
25199548
10.

BRCA1 and BRCA2 mutations and the risk for colorectal cancer.

Sopik V, Phelan C, Cybulski C, Narod SA.

Clin Genet. 2015 May;87(5):411-8. doi: 10.1111/cge.12497. Epub 2014 Oct 21.

PMID:
25195694
11.

Carrier screening of RTEL1 mutations in the Ashkenazi Jewish population.

Fedick AM, Shi L, Jalas C, Treff NR, Ekstein J, Kornreich R, Edelmann L, Mehta L, Savage SA.

Clin Genet. 2014 Jul 22. doi: 10.1111/cge.12459. [Epub ahead of print]

PMID:
25047097
12.

Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.

Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.

Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.

PMID:
24946157
13.

Barriers to cancer screening among orthodox jewish women.

Tkatch R, Hudson J, Katz A, Berry-Bobovski L, Vichich J, Eggly S, Penner LA, Albrecht TL.

J Community Health. 2014 Dec;39(6):1200-8. doi: 10.1007/s10900-014-9879-x.

PMID:
24845763
14.

BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.

Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H.

Cancer. 2014 Jul 1;120(13):1960-7. doi: 10.1002/cncr.28662. Epub 2014 Apr 15.

15.

Cultural aspects of healthy BRCA carriers from two ethnocultural groups.

Navarro de Souza A, Groleau D, Loiselle CG, Foulkes WD, Wong N.

Qual Health Res. 2014 May;24(5):665-81. doi: 10.1177/1049732314528756. Epub 2014 Apr 1.

PMID:
24692182
16.

Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations.

Aviel-Ronen S, Soriano D, Shmuel E, Schonman R, Rosenblatt K, Zadok O, Vituri A, Seidman D, Barshack I, Cohen Y.

Pathol Res Pract. 2014 Apr;210(4):250-5. doi: 10.1016/j.prp.2013.12.011. Epub 2014 Jan 10.

PMID:
24472143
17.

BRCA mutation carriers do not have compromised ovarian reserve.

Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T.

Int J Gynecol Cancer. 2014 Feb;24(2):233-7. doi: 10.1097/IGC.0000000000000058.

PMID:
24378620
18.

BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study.

Dagan E, Cohen Y, Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R.

Eur J Hum Genet. 2014 Feb;22(2):277-9. doi: 10.1038/ejhg.2013.281. Epub 2013 Nov 27. Erratum in: Eur J Hum Genet. 2014 Feb;22(2):295.

19.

Commentary: case-control studies of screening for colorectal cancer: tailoring the design and analysis to the specific research question.

Weiss NS.

Epidemiology. 2013 Nov;24(6):894-7. doi: 10.1097/EDE.0b013e3182a777b2. No abstract available.

20.

The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews.

Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D, Arber N, Kraus S.

Eur J Cancer. 2013 Nov;49(17):3680-5. doi: 10.1016/j.ejca.2013.06.040. Epub 2013 Jul 26.

PMID:
23896379
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk